FDA Releases Software Tips for Safer Medical Devices
Published Date: 9/24/2025
Notice
Summary
The FDA just released new guidance to help medical device makers use computer software safely and smartly during production and quality checks. This update encourages using fresh tech to make devices better and faster while keeping everything legal and safe. If you work with medical device software, get ready to follow these new tips to stay ahead and keep patients happy!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA issues software-assurance recommendations
The FDA released final guidance called "Computer Software Assurance for Production and Quality System Software" that gives recommendations on computer software assurance for computers and automated data processing systems used in medical device production and quality systems. If you make or run medical device production or quality-system software, this guidance tells you recommended practices to follow.
Guidance aims to expand patient access
The FDA says these recommendations are intended to help foster adoption of innovative technologies and promote patient access to high-quality medical devices. The guidance also says it should help manufacturers keep pace with rapidly changing technology while promoting compliance with FDA laws and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2025-18465, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Partially Closed Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a two-day virtual meeting on January 26-27, 2026. The first day is open to the public and will share updates and scientific talks, while the second day is closed to review grant applications confidentially. Researchers and the public can join or send comments, with no cost to attend and easy online access.
Next: 2025-18470, New Functionality Pertaining to Electronic Refunds in the Automated Commercial Environment
U.S. Customs and Border Protection is making it easier for businesses to get electronic refunds by adding a new ACH Refund Authorization tab in the ACE Portal. This means faster, smoother refunds through Automated Clearinghouse (ACH) payments. If you import goods, get ready to save time and possibly speed up your money back starting soon!